|
業務類別
|
Biotechnology |
|
業務概覽
|
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others. |
| 公司地址
| 88 Sidney Street, Cambridge, MA, USA, 02139 |
| 電話號碼
| +1 617 649-8600 |
| 傳真號碼
| +1 617 344-0070 |
| 公司網頁
| https://www.agios.com |
| 員工數量
| 540 |
| Mr. James William Burns |
Chief Legal Officer |
美元 511.92K |
25/04/2025 |
| Dr. Krishnan Viswanadhan |
Chief Corporate Development and Strategy Officer |
-- |
25/04/2025 |
| Ms. Cecilia Jones |
Chief Financial Officer |
美元 503.88K |
12/02/2026 |
| Mr. Brian Goff |
Chief Executive Officer and Director |
美元 822.20K |
12/02/2026 |
| Ms. Tsveta Milanova |
Chief Commercial Officer |
美元 525.30K |
25/04/2025 |
| Dr. Sarah Gheuens, M.D.,PhD |
Chief Medical Officer and Head of Research and Development |
美元 583.50K |
25/04/2025 |
| Mr. T. J. Washburn |
Principal Accounting Officer, Vice President and Controller |
-- |
12/02/2026 |
|
|
| Dr. Rahul D. Ballal, PhD |
Independent Director |
12/02/2026 |
| Ms. Catherine Owen |
Independent Director |
12/02/2026 |
| Ms. Kaye Foster |
Lead Independent Director |
12/02/2026 |
| Mr. Jeffrey D. Capello |
Independent Director |
12/02/2026 |
| Dr. Jacqualyn A. Fouse, PhD |
Chairman of the Board |
12/02/2026 |
| Dr. Jay T. Backstrom, M.D.,M.P.H. |
Director |
12/02/2026 |
| Mr. Brian Goff |
Chief Executive Officer and Director |
12/02/2026 |
| Ms. Cynthia Smith |
Independent Director |
12/02/2026 |
| Dr. Maykin Ho, PhD |
Independent Director |
12/02/2026 |
| Dr. David T. Scadden, M.D. |
Independent Director |
12/02/2026 |
|
|
|
|
